Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

Abstract:

:Whereas first-line chemotherapy (CT) with single-agent gemcitabine or gemcitabine-based combinations provides a proven benefit in patients with locally advanced or metastatic pancreatic cancer (PC), the role of salvage CT after gemcitabine-failure is not well-established and to date no regimen has emerged as preferred in this setting. Several clinical trials have investigated the efficacy and toxicity-profile of second-line CT and indicated that selected patients may obtain significant benefit from it, also with regard to survival. However, definitive results from large randomized phase III studies are still lacking, and the evidence for clinical benefit of salvage CT is based on small phase II trials that evaluated different treatment schedules in heterogeneous populations. The main goal of this paper is reviewing this topic.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Custodio A,Puente J,Sastre J,Díaz-Rubio E

doi

10.1016/j.ctrv.2009.08.012

subject

Has Abstract

pub_date

2009-12-01 00:00:00

pages

676-84

issue

8

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(09)00126-1

journal_volume

35

pub_type

杂志文章,评审
  • Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis.

    abstract:PURPOSE:Neoadjuvant chemotherapy followed by surgery (NACT + S) has been compared with definitive chemoradiothherapy (CRT) in randomized clinical trials (RCTs) in stage IB2, IIA and IIB cervical cancer (1994 Figo stage). Our aim was to evaluate efficacy and toxicity of NACT + S and CRT and identify differences in clini...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ctrv.2019.101945

    authors: Marchetti C,Fagotti A,Tombolini V,Scambia G,De Felice F

    更新日期:2020-02-01 00:00:00

  • Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review.

    abstract::Recently, non-small cell lung cancer (NSCLC) has been partly subclassified into molecularly-defined oncogene "addicted" tumors for which targeted agents are available. Tyrosine kinase inhibitors (TKI) are currently approved for patients with an activating epidermal growth factor receptor (EGFR) mutation or anaplastic ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.05.005

    authors: Hendriks LE,Schoenmaekers J,Zindler JD,Eekers DB,Hoeben A,De Ruysscher DK,Dingemans AM

    更新日期:2015-07-01 00:00:00

  • Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding?

    abstract::An increasing number of women are diagnosed with cancer during pregnancy and lactation. Women are usually advised to interrupt breastfeeding during systemic anticancer treatment for fear of serious adverse effects to the nursed infant. However, the issue is poorly addressed in the literature and very few studies have ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.10.002

    authors: Pistilli B,Bellettini G,Giovannetti E,Codacci-Pisanelli G,Azim HA Jr,Benedetti G,Sarno MA,Peccatori FA

    更新日期:2013-05-01 00:00:00

  • Prevention of chemotherapy and radiation toxicity with glutamine.

    abstract:GOALS OF THE WORK:Malignancy produces a state of physiologic stress that is characterized by a relative deficiency of glutamine, a condition that is further exacerbated by the effects of cancer treatment. Glutamine deficiency may impact on normal tissue tolerance to antitumor treatment, and may lead to dose reductions ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00133-6

    authors: Savarese DM,Savy G,Vahdat L,Wischmeyer PE,Corey B

    更新日期:2003-12-01 00:00:00

  • Patient-controlled analgesia (PCA) in the domiciliary care of tumour patients.

    abstract::Patient-controlled analgesia (PCA) was administered in the domiciliary environment in 143 pre-terminally and terminally ill tumour patients suffering either from excruciating chronic pain or severe chronic/acute complex pain that could not be relieved adequately by oral analgesia. Morphine solutions were infused subcu...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/s0305-7372(96)90076-6

    authors: Meuret G,Jocham H

    更新日期:1996-01-01 00:00:00

  • Pancreatic cancer: current and future treatment strategies.

    abstract::Pancreatic cancer is a disease with a high mortality rate and short survival, as a result of the high incidence of metastatic disease at diagnosis, the fulminant clinical course and the lack of successful therapeutic strategies. The administration of chemotherapeutic agents for the treatment of advanced disease has fa...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.02.005

    authors: Pliarchopoulou K,Pectasides D

    更新日期:2009-08-01 00:00:00

  • Pediatric sarcomas and related tumors of the head and neck.

    abstract::Sarcomas of the head and neck region are a rare group of tumors in children and present challenges with regard to evaluation and treatment. Rhabdomyosarcomas are the most common sarcomas of the head and neck in children. Presence of metastases and complete surgical resectability continue to be the most relevant clinic...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.04.005

    authors: Huh WW,Fitzgerald N,Mahajan A,Sturgis EM,Beverly Raney R,Anderson PM

    更新日期:2011-10-01 00:00:00

  • New approaches to the systemic treatment of melanoma.

    abstract::Metastatic melanoma is an incurable condition with a median survival of about 6 months. Chemotherapy can result in objective tumour responses but only in a minority of cases and remissions are short-lived, 3-6 months. DTJC is the most active single agent with response rates of 15-20% and although combination chemother...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.1999.0138

    authors: Chowdhury S,Vaughan MM,Gore ME

    更新日期:1999-10-01 00:00:00

  • p53 as a target for the treatment of cancer.

    abstract::TP53 (p53) is the most frequently mutated gene in cancer, being altered in approximately 50% of human malignancies. In most, if not all, cancers lacking mutation, wild-type (WT) p53 is inactivated by interaction with cellular (MDM2/MDM4) or viral proteins, leading to its degradation. Because of its near universal alte...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.10.004

    authors: Duffy MJ,Synnott NC,McGowan PM,Crown J,O'Connor D,Gallagher WM

    更新日期:2014-12-01 00:00:00

  • The role of bone markers in metastatic bone disease.

    abstract::Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bon...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(06)80001-0

    authors: Coleman RE

    更新日期:2006-01-01 00:00:00

  • The expanding role of immunotherapy.

    abstract::The use of agents able to modulate the immune system to induce or potentiate its anti-tumour activity is not a new strategy in oncology. However, the development of new agents such as immune checkpoint inhibitors has achieved unprecedented efficacy results in a wide variety of tumours, dramatically changing the landsc...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.01.008

    authors: Martin-Liberal J,Ochoa de Olza M,Hierro C,Gros A,Rodon J,Tabernero J

    更新日期:2017-03-01 00:00:00

  • An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.

    abstract::Malignant Pleural Mesothelioma (MPM) is an aggressive tumour with poor prognosis and increasing incidence in industrialized countries because of the previous widespread exposure to asbestos fibres and to the long lag period from time of exposure and the diagnosis of the disease. MPM shows high refractoriety to systemi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.03.001

    authors: Pasello G,Ceresoli GL,Favaretto A

    更新日期:2013-02-01 00:00:00

  • DNA repair and cancer stem-like cells--potential partners in glioma drug resistance?

    abstract::Glioblastoma is the most malignant and frequent primary brain tumour in adults. Current treatment remains insufficient as these tumours display a diffuse infiltrative growth pattern and tend to recur despite extensive debulking surgery followed by radio- and chemotherapy. The alkylating agents carmustine (1,3-bis-(2-c...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.03.125

    authors: Johannessen TC,Bjerkvig R,Tysnes BB

    更新日期:2008-10-01 00:00:00

  • Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.

    abstract::Resistance to tyrosine-kinase inhibitors remains an open issue in the treatment of patients with gastrointestinal stromal tumors. The complex biology of disease in the multi-resistant setting has led a progressively growing urgency and interest in development combined or integrated therapies. This mini-review outlines...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.10.004

    authors: Pantaleo MA,Nannini M,Di Battista M,Catena F,Biasco G

    更新日期:2010-02-01 00:00:00

  • Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.

    abstract:BACKGROUND:The second decade of 2000s is witnessing a new ovarian cancer (OC) paradigm shift thanks to the results recently obtained by a new class of targeted agents: the Poly(ADP-ribose)polymerase (PARP)-Inhibitors (PARPi). Aim of this meta-analysis is to analyze available results obtained with PARPi, administered al...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ctrv.2020.102040

    authors: Ruscito I,Bellati F,Ray-Coquard I,Mirza MR,du Bois A,Gasparri ML,Costanzi F,De Marco MP,Nuti M,Caserta D,Pignata S,Dorigo O,Sehouli J,Braicu EI

    更新日期:2020-07-01 00:00:00

  • Health promotion and psychological interventions for adolescent and young adult cancer survivors: A systematic literature review.

    abstract:BACKGROUND:The effects of cancer and treatment have severe and long lasting negative impacts on quality of life. Adolescents and Young Adults (AYA) have high survival rates but may not reach their full life potential because of these consequences. This review aims to identify, appraise and synthesise the effects of hea...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.02.011

    authors: Bradford NK,Chan RJ

    更新日期:2017-04-01 00:00:00

  • The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review.

    abstract::Tumour budding reflects a detachment of tumour cells at the invasive front of carcinomas and is presumed to be an early step in the metastatic process. Tumour budding has received some attention in colorectal cancer as it has been proposed as an additional prognostic factor in colorectal cancer that may stratify patie...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.12.007

    authors: van Wyk HC,Park J,Roxburgh C,Horgan P,Foulis A,McMillan DC

    更新日期:2015-02-01 00:00:00

  • The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.

    abstract::Gastric cancer (GC) represents the fifth cause of cancer-related death worldwide. Molecular biology has become a central area of research in GC and there are currently at least three major classifications available to elucidate the mechanisms that drive GC oncogenesis. Further, tumor microenvironment seems to play a c...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2020.102015

    authors: Gambardella V,Castillo J,Tarazona N,Gimeno-Valiente F,Martínez-Ciarpaglini C,Cabeza-Segura M,Roselló S,Roda D,Huerta M,Cervantes A,Fleitas T

    更新日期:2020-06-01 00:00:00

  • Management of a novel immune deficiency with IL-2 therapy.

    abstract::The present study describes a female child, who had a primary defect in the ability of her T-cells to secrete interleukin-2. Numbers of B- and T-cells were normal, but their functions were severely deficient. The patient had decreased immunoglobulins and poor ability to mount antibody responses. Phytohemagglutinin (PH...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(89)90034-0

    authors: Pahwa R,Paradise C,Good RA

    更新日期:1989-06-01 00:00:00

  • Rectal and colon cancer: Not just a different anatomic site.

    abstract::Due to differences in anatomy, primary rectal and colon cancer require different staging procedures, different neo-adjuvant treatment and different surgical approaches. For example, neoadjuvant radiotherapy or chemoradiotherapy is administered solely for rectal cancer. Neoadjuvant therapy and total mesorectal excision...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.06.007

    authors: Tamas K,Walenkamp AM,de Vries EG,van Vugt MA,Beets-Tan RG,van Etten B,de Groot DJ,Hospers GA

    更新日期:2015-09-01 00:00:00

  • Current status and future perspectives in gastric cancer management.

    abstract::Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Environmental and Helicobacter pylori (Hp) acting early in life in a multistep and multifactorial process may cause intestinal type carcinomas, whereas genetic abnormalities are related more...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2000.0164

    authors: Roukos DH

    更新日期:2000-08-01 00:00:00

  • Cancer stem cells niche: a target for novel cancer therapeutics.

    abstract::Nowadays, cancer has been a frequent disease, and the first or second most common cause of death worldwide. Despite a better understanding of the biology of cancer cells, the therapy of most cancers has not significantly changed for the past four decades. It is because conventional chemotherapies and/or radiation ther...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.10.004

    authors: Yi SY,Hao YB,Nan KJ,Fan TL

    更新日期:2013-05-01 00:00:00

  • Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.

    abstract::Low Grade Serous Ovarian Carcinoma, LGSOC, is certainly a rare disease, accounting for only a small proportion of all ovarian carcinomas, nevertheless in the last decade we have acquired many data about its molecular and clinical features and it has been largely accepted that it has distinct pathogenesis, genetic aber...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.12.003

    authors: Della Pepa C,Tonini G,Santini D,Losito S,Pisano C,Di Napoli M,Cecere SC,Gargiulo P,Pignata S

    更新日期:2015-02-01 00:00:00

  • Low dose cyclophosphamide: Mechanisms of T cell modulation.

    abstract::Cyclophosphamide is considered one of the most successful chemotherapy drugs and is listed on the World Health Organisations List of Essential Medicines. Since its initial synthesis in 1958, it has been widely used to treat a range of cancers but its use has been declining due to the advent of platinum based and other...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.11.005

    authors: Madondo MT,Quinn M,Plebanski M

    更新日期:2016-01-01 00:00:00

  • Cellular immunotherapy in breast cancer: The quest for consistent biomarkers.

    abstract::Breast cancer is the most common malignancy in women worldwide, with a relatively high proportion of patients experiencing resistance to standard treatments. Cellular immunotherapy (CI), which is based on the extraction, modification, and re-infusion of the patient's immune cells, is showing promising results in these...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2020.102089

    authors: Venetis K,Invernizzi M,Sajjadi E,Curigliano G,Fusco N

    更新日期:2020-11-01 00:00:00

  • Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials.

    abstract:BACKGROUND:The colony-stimulating factors (CSFs) are widely utilized to prevent neutropenic complications in both adults and children, but randomized controlled trials in the pediatric setting have reported varied results. A systematic review of the literature and meta-analysis were conducted to definitively assess the...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2006.03.002

    authors: Wittman B,Horan J,Lyman GH

    更新日期:2006-06-01 00:00:00

  • AR-V7 and prostate cancer: The watershed for treatment selection?

    abstract::The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity with the next-generation hormonal therapies (abiraterone acetate and enzalutamide), resistance to these agents limits therapeutic effica...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.12.003

    authors: Ciccarese C,Santoni M,Brunelli M,Buti S,Modena A,Nabissi M,Artibani W,Martignoni G,Montironi R,Tortora G,Massari F

    更新日期:2016-02-01 00:00:00

  • Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials.

    abstract:PURPOSE:To conduct a systematic review and meta-analysis of all phase III randomized controlled trials comparing efficacy of early versus late first-line or initial treatments for cancer. METHODS:A comprehensive literature search of MEDLINE and Cochrane library databases was performed (1966-2008). Data was extracted a...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2010.04.001

    authors: Mhaskar AR,Quinn G,Vadaparampil S,Djulbegovic B,Gwede CK,Kumar A

    更新日期:2010-12-01 00:00:00

  • Metastatic colorectal cancer.

    abstract::Metastatic colorectal cancer remains a public-health issue on a global scale. With development of a new generation of cytotoxic agents, survival has improved for patients with metastatic disease. How to maximize the benefit of chemotherapy with acceptable toxicity remains incompletely answered. Hepatic resection can p...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.07.005

    authors: Saletti P,Cavalli F

    更新日期:2006-11-01 00:00:00

  • Targeting uPA/uPAR in prostate cancer.

    abstract::Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to secondary disease (metastases). The invasive ability of tumour cells plays a key role in CaP met...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.06.003

    authors: Li Y,Cozzi PJ

    更新日期:2007-10-01 00:00:00